Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: A quantitative angiographic analysis

Circulation

Volumn 93, Issue 5, 1996, Pages 889-897

  Violaris, Andonis G ^b   Melkert, Rein ^a   Herrman, Jean Paul R ^b   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Erasmus University Rotterdam ^*

Author keywords

angioplasty; meta analysis; thrombus angiography; trials

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0029981348     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.5.889     Document Type: Article

References (42)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61-68.
2. de Feyter PJ, Serruys PW, van der Brand M, Hugenholtz PG. Percutaneous transluminal coronary angioplasty for unstable angina. Am J Cardiol. 1991;68:125B-135B.
3. Morrison DA. Coronary angioplasty for medically refractory unstable angina within 30 days of acute myocardial infarction. Am Heart J. 1990;120:256-261.
4. Myler RK, Shaw RE, Stertzer SH, Bashour TT, Ryan C, Hecht HS, Cumberland DC. Unstable angina and coronary angioplasty. Circulation. 1990;82(suppl II):II-88-II-95.
5. Zijlstra F, Jan de Boer M, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680-684.
6. Arora RR, Platko WP, Bhadwar K, Simpfendorfer C. Role of intracoronary thrombus in acute complications during percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn. 1989;16:226-229.
7. Ellis SG, Roubin GS, King SB, Douglas JS Jr, Weintraub WS, Thomas RG, Cox WR. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation. 1988;77:372-379.
8. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17:77B-88B.
9. Willerson JT, Yao S-K, McNatt J, Benedict CR, Anderson HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic flow alterations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A. 1991;88: 10624-10628.
10. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
11. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24:1398-1405.
12. 2-receptor blockade: a randomized, double-blind, placebo-controlled trial: Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation. 1991; 84:1568-1580.
13. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 1992;86:100-110.
14. Serruys PW, Klein W, Tijssen JP, Rutsch W, Heyndrickx GR, Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H, Eichhorn E, Willerson JT, Anderson HV, Khaja F, Alexander RW, Baim D, Melkert R, van Oene JC, van Gool R. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicenter randomized double-blind placebo-controlled trial: the Post-Angioplasty Restenosis Ketanserin (PARK) trial. Circulation. 1993;88:1588-1601.
15. Faxon DP, on behalf of the MARCATOR Study Group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995; 25:362-369.
16. Serruys PW, Foley DP, deFeyter PJ, eds. Quantitative Coronary Angiography in Clinical Practise. Dordrecht, Netherlands: Kluwer Academic Press; 1994.
17. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol. 1985;56:403-406.
18. den Heijer P, Foley DP, Escaned J, Hillege HL, van Dijk RB, Serruys PW, Lie KI. Angioscopic versus angiographic detection of intimai dissection and intracoronary thrombus. J Am Coll Cardiol. 1994;24:649-654.
19. TIMI Study Group. The thrombolysis and myocardial infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
20. Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation. 1993;88:1310-1323.
21. Serruys PW, Foley DP, de Feyter PJ. Restenosis after coronary angioplasty: a proposal of new comparative approaches based on quantitative angiography. Br Heart J. 1992;68:417-424.
22. Foley DP, Melkert R, Serruys PW, on behalf of the CARPORT, MERCATOR, MARCATOR and PARK Investigators. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation. 1994;90:1239-1251.
23. Nakagawa Y, Kimura T, Nosaka H, Nobuyoshi M. Predictor of acute reocclusion after angioplasty for acute myocardial infarction. Eur Heart J. 1994;15(suppl):308. Abstract.
24. Zimarino M, Corcos T, Favereau X, Guerin Y, Tamburino C, Toussaint M, Funck F, Eiferman C. Silent early reocclusion after successful coronary angioplasty of chronic total occlusions. Eur Heart J. 1994;15(suppl):281. Abstract.
25. Sanborn TA. Recanalization of arterial occlusions: pathologic basis and contributing factors. J Am Coll Cardiol. 1989;13:1558-1560.
26. Badimon L, Lassila R, Badimon J, Vallabhajosua S, Chesebro JH, Fuster V. Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation. 1988;78(suppl II):II-119. Abstract.
27. Mruk JS, Chesebro JH, Webster MWI. Platelet aggregation and interaction with the coagulation system: implications for anti-thrombotic therapy in arterial thrombosis. Coron Artery Dis. 1990;1: 149-158.
28. Goldsmith HL, Turritto VT. Rheologic aspects of thrombosis and haemostasis: basic principles and applications. Thromb Haemost. 1986;56:415-435.
29. Carvalho H, Fajadet J, Caillard JB, Jordan C, Laurent JP, Cassagneau B, Robert G, Marco J. Predictors of thrombotic occlusion following Gianturco-Roubin stent implantation. Eur Heart J. 1994; 15(suppl):536. Abstract.
30. Serruys PW, Di Mario C, Kern MJ. Intracoronary Doppler. In: Topol EJ, ed. Tatbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders; 1994:1069-1121.
31. Bates ER, Califf RM, Stack RS, Aronson L, George BS, Candela RJ, Kereiakes DJ, Abbottsmith CW, Anderson L, Pitt B, O'Neill WW, Topol EJ, and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol. 1989;13:12-18.
32. Violaris AG, Melkert R, Serruys PW. Long-term luminal renarrowing following successful elective coronary angioplasty of total occlusions: a quantitative angiographic analysis. Circulation. 1995; 91:2140-2150.
33. Tenaglia AN, Fortin DF, Frid DJ, Gardner LH, Nelson CL, Tcheng JE, Califf RM. Restenosis and long term outcome following successful treatment of abrupt closure after angioplasty. Circulation. 1991;84(suppl II):II-131. Abstract.
34. Baalbaki HA, Weintraub WS, Tao X, Ghazzal ZMB, Liberman HA, Douglas JS, King SB III. Restenosis after acute closure and successful reopening: implications for new devices. Circulation. 1990;82(suppl III):III-314. Abstract.
35. Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J. 1989;117: 769-776.
36. den Heijer P, van Dijk RB, Hillege HL, Pentinga ML, Serruys PW, Lie KI. Serial angioscopic and angiographic observations during the first hour after successful coronary angioplasty: a preamble to a multicenter trial addressing angioscopic markers for restenosis. Am Heart J. 1994;128:656-663.
37. Johnson DE, Hinohara T, Selmon MR, Braden LJ, Simpson JB. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study. J Am Coll Cardiol. 1990;15:419-425.
38. Deligonul U, Gabliani GI, Caralis DG, Kern MJ, Vandormael MG. Percutaneous transluminal coronary angioplasty in patients with intracoronary thrombus. Am J Cardiol. 1988;62:474-476.
39. Detre KM, Holmes DR Jr, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM, Myler RK. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990;82: 739-750.
40. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol. 1991;17:89B-95B.
41. Ellis SG, Tcheng JE, Navetta FI, Muller DWM, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis. 1993;4:167-175.
42. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet. 1994;343:881-886.